Dasiglucagon
- Generic Name
- Dasiglucagon
- Brand Names
- Zegalogue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1544300-84-6
- Unique Ingredient Identifier
- AD4J2O47FQ
- Background
Dasiglucagon is a glucagon analog that acts to increase blood sugar levels. It consists of 29 amino acids similar to endogenous glucagon; however, it contains seven substituted amino acids for improved physical and chemical stability in its drug formulation. In March 2021, the FDA approved dasiglucagon to treat severe hypoglycemia in patients six years and o...
- Indication
Dasiglucagon is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
- Associated Conditions
- Severe Hypoglycemia
- Associated Therapies
- -
Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 38
- Registration Number
- NCT06588504
- Locations
- 🇯🇵
Hakata Clinic, Fukuoka, Japan
A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Inreda Diabetic B.V.
- Registration Number
- NCT05454709
- Locations
- 🇳🇱
ZGT hospital, Almelo, Overijssel, Netherlands
A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 8
- Registration Number
- NCT05378672
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸Cook Childrens Health Care System, Fort Worth, Texas, United States
Treatment of Post-bariatric Hypoglycaemia
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Filip Krag Knop
- Target Recruit Count
- 24
- Registration Number
- NCT04836273
- Locations
- 🇩🇰
Center for Clinical Metabolic Research, Herlev-Gentofte Hospital, Hellerup, Denmark
Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Zealand Pharma
- Registration Number
- NCT04824872
Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 Diabetes
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 24
- Registration Number
- NCT04764968
- Locations
- 🇩🇰
Steno Diabetes Center Copenhagen, Gentofte, Denmark
Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 20
- Registration Number
- NCT04449692
- Locations
- 🇩🇰
Steno Diabetes Center Copenhagen, Gentofte, Denmark
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 12
- Registration Number
- NCT04172441
- Locations
- 🇩🇪
University Children's Hospital, Düsseldorf, Germany
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 44
- Registration Number
- NCT03941236
- Locations
- 🇩🇪
University Hospital Düsseldorf, Department of Pediatrics, Düsseldorf, Germany
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
🇮🇱Hadassah Medical Center, Jerusalem, Israel
A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 92
- Registration Number
- NCT03895697
- Locations
- 🇨🇦
LMC Diabetes & Manna Research, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.